OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
60
Results
Show all
Save search
Copy query
Show results for
Unknown
(60)
Publication Date
Release Date
2021
(7)
2018
(6)
2015
(6)
2014
(5)
2011
(5)
2022
(4)
2016
(4)
2023
(3)
2020
(3)
2017
(3)
2009
(3)
2025
(2)
2010
(2)
2008
(2)
2024
(1)
2019
(1)
2013
(1)
2012
(1)
2003
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
High Prevalence of Dyslipidemia and Insulin Resistance in HIV-infected Prepubertal African Children on Antiretroviral Therapy.
Not available
S-EPMC4707556
|
biostudies-literature
Cite
Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data.
Not available
S-EPMC3117802
|
biostudies-literature
Cite
Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy.
Not available
S-EPMC2687257
|
biostudies-literature
Cite
HIV viral kinetics and T cell dynamics in antiretroviral naive persons starting an integrase strand transfer inhibitor and protease inhibitor regimen.
Not available
S-EPMC5613656
|
biostudies-literature
Cite
Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Not available
S-EPMC3196673
|
biostudies-literature
Cite
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Not available
S-EPMC6988963
|
biostudies-literature
Cite
PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM.
Not available
S-EPMC7442274
|
biostudies-literature
Cite
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Not available
S-EPMC7179327
|
biostudies-literature
Cite
Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy.
Not available
S-EPMC3203388
|
biostudies-literature
Cite
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Not available
S-EPMC5853584
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets